Company intelligence / Profile preview

Senti Holdings

South San Francisco, California, United States

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Senti Biosciences is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit technology platform. By programming cells with biological logic gates, the company aims to create "smart" therapies that can sense and respond to disease environments with high precision. Their lead programs utilize off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells designed to enhance targeting and reduce off-tumor toxicity. Senti Bio is currently advancing clinical trials for hematologic malignancies and exploring applications in solid tumors.

Therapeutic areas: HematologyOncology
Modalities: Cell therapyNK cell therapyGene therapy
Industry: Biotech

Partnerships

BayerBlueRock TherapeuticsSpark TherapeuticsGeneFab

Beyond the preview

Go deeper on Senti Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senti Holdings.

Explore the full profile